Literature DB >> 9145774

Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors.

A Langlois1, L Diop, N Friese, X Pascaud, J L Junien, S G Dahl, P J Rivière.   

Abstract

The effect of fedotozine on visceral hypersensitivity was evaluated in conscious rats. One hour after colonic irritation (0.6% acetic acid intracolonically), a 30 mmHg colonic distension was applied for 10 min. Irritation increased the number of abdominal contractions induced by colonic distension (23.4 +/- 4.1 versus 4.8 +/- 1.4 in saline-treated rats, P < 0.001). Facilitation of colonic pain was reversed in a dose-dependent manner by fedotozine ((+)-(-1R1)-1-phenyl-1-[(3,4,5-trimethoxy)benzyloxymethyl]-N ,N-dimethyl-n-propylamine), (+/-)-U-50,488H (trans-(+/-)-3,4-dichloro-N-methyl-N-(2-1-pyrrolidinyl]cyclohexyl)benzen eacetamide) and morphine (respective ED50 values 0.67, 0.51 and 0.23 mg/kg s.c.). The kappa-opioid receptor antagonist, nor-binaltorphimine, abolished the effects of fedotozine and (+/-)-U-50,488H but not those of morphine. Low doses of naloxone (30 microg/kg s.c.) blocked the effect of morphine but not of fedotozine or (+/-)-U-50,488H. After intracerebroventricular administration, morphine was very potent (ED50 1.7 microg/rat), (+/-)-U-50,488H poorly active (58% of antinociception at 300 microg/rat) and fedotozine inactive up to 300 microg/rat. These results show that fedotozine blocks hypersensitive visceral pain by acting on peripheral kappa-opioid receptors in animals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145774     DOI: 10.1016/s0014-2999(97)00089-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 2.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

Review 3.  Stress and visceral pain: from animal models to clinical therapies.

Authors:  Muriel Larauche; Agata Mulak; Yvette Taché
Journal:  Exp Neurol       Date:  2011-05-06       Impact factor: 5.330

4.  Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

Review 5.  Visceral nociception.

Authors:  K N Westlund
Journal:  Curr Rev Pain       Date:  2000

Review 6.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

Review 7.  Pharmacotherapy: non-serotonergic mechanisms.

Authors:  R Spiller
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 8.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

9.  Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia.

Authors:  N J Talley; R S Choung; M Camilleri; R A Dierkhising; A R Zinsmeister
Journal:  Aliment Pharmacol Ther       Date:  2008-03-07       Impact factor: 8.171

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.